Studies investigating the treatment of elderly patients with rheumatoid arthritis (RA) have shown that compared to younger patients, initial treatment is less aggressive, and they are less likely to receive anti-tumor necrosis factor-α therapy due to concerns of adverse events and the assumption of comorbidities33,34. This evidence concerns the gene TNF and rheumatoid arthritis.